Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam

Inclusion Criteria: * Healthy female subject based on a complete medical history, physical examination, ECG, and clinical laboratory tests * Age: 45 to 70 years (inclusive) at the first screening visit * Minimum body weight 50 kg with Body mass index (BMI) above or equal to 18.5 kg/m², and below or equal to 30 kg/m² at the first screening visit * Postmenopausal state, revealed indicated by either: * medical history, if applicable (natural menopause at least 12 months prior to first study drug administration, for women younger than 60 years confirmed by follicle stimulating hormone (FSH) \>40 IU/L AND estradiol ≤ 20 pg/mL; or * surgical menopause by bilateral ovariectomy at least 3 months prior to first study drug administration) Exclusion Criteria: * Relevant diseases within the last 4 weeks prior to the first study drug administration, i.e. any disease requiring treatment by a health-care provider * Febrile illness within 1 week before the first study drug administration * Known severe allergies, non-allergic drug reactions, or multiple drug allergies * Presence or history of thrombosis, thrombophlebitis, thromboembolic diseases of veins and/or arteries, e.g. deep vein thrombosis, stroke, myocardial infarction, pulmonary embolism, transient ischemic attack, angina pectoris * Presence or history of conditions that increase the risk of thromboembolic diseases, e.g. disturbances of the coagulation system, thromboembolic diseases in close relatives at age ≤50 years\], valvular heart disease, atrial fibrillation, cardiac dysfunction) * Presence, history, or suspected presence of malignant tumors or tumors of the liver and pituitary * Presence or history of liver disease e.g. disturbances of the bilirubin excretion (Dubin-Johnson and Rotor syndromes), cholecystectomy ; cholestasis, idiopathic icterus or pruritus during a previous pregnancy or estrogen-progestogen treatment * Relevant kidney diseases or renal injury associated with multisystem diseases/disorders, e.g. glomerulonephritis systemic lupus erythematous, diabetic nephropathy. A history of a single episode of uncomplicated nephrolithiasis does not prevent participation * Known metabolic disorder, e.g. diabetes mellitus, severe hypertriglyceridemia * Migraine with neurologic symptoms * Clinically significant depression, current or in the last year * Known current thyroid disorders which require treatment. Subjects with an euthyroid struma who do not need any treatment can participate. * Chronic respiratory insufficiency * History of porphyria * Contraindications for midazolam, e.g. myasthenia gravis, and sleep apnea